Konica Minolta Amends Lock-Up Terms for Tempus Stock in Ambry Genetics Sale
Konica Minolta has amended the lock-up terms for Tempus stock received in the sale of its subsidiary, Ambry Genetics, to Tempus AI. The transaction, completed on February 3, 2025, was valued at $600 million. Initially, $125 million in stock was sold post-registration, while the remaining $100 million, originally under a one-year lock-up, will now be subject to sale restrictions from December 2, 2025, becoming freely saleable one year post-transaction.
Konica Minolta has provided an update regarding the transfer of its subsidiary, Ambry Genetics Corporation, to Tempus AI, Inc. The transaction, completed on February 3, 2025, involved a sale price of US$600 million, with US$375 million paid in cash and US$225 million in Tempus Class A Common stock. Of the stock portion, US$125 million became available for sale after the registration process and was fully sold during the first quarter of the fiscal year ending March 2026. The remaining US$100 million in stock was originally subject to a one-year lock-up, but the terms have been amended so that these shares are now subject to certain restrictions on sale on and after December 2, 2025, and will become freely saleable one year after the transaction’s closing date. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Konica Minolta Inc. published the original content used to generate this news brief on December 08, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
